Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Decreases By 10.1%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 14,200 shares, a decrease of 10.1% from the July 15th total of 15,800 shares. Based on an average trading volume of 56,200 shares, the days-to-cover ratio is presently 0.3 days.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of NASDAQ GNOM traded up $0.07 during mid-day trading on Friday, reaching $11.37. The company had a trading volume of 59,242 shares, compared to its average volume of 63,695. Global X Genomics & Biotechnology ETF has a twelve month low of $8.63 and a twelve month high of $12.53. The stock has a market capitalization of $84.59 million, a PE ratio of -4.86 and a beta of 1.03. The stock’s 50 day moving average is $10.91 and its 200-day moving average is $10.91.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

A number of hedge funds have recently modified their holdings of GNOM. One Capital Management LLC increased its stake in shares of Global X Genomics & Biotechnology ETF by 22.1% in the second quarter. One Capital Management LLC now owns 680,311 shares of the company’s stock worth $7,102,000 after acquiring an additional 123,339 shares during the last quarter. Corrado Advisors LLC acquired a new position in Global X Genomics & Biotechnology ETF during the fourth quarter worth $638,000. Mirae Asset Global Investments Co. Ltd. increased its position in Global X Genomics & Biotechnology ETF by 16.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 377,749 shares of the company’s stock worth $4,431,000 after buying an additional 53,178 shares during the last quarter. James J. Burns & Company LLC acquired a new position in Global X Genomics & Biotechnology ETF during the second quarter worth $181,000. Finally, Archford Capital Strategies LLC increased its position in Global X Genomics & Biotechnology ETF by 59.1% during the second quarter. Archford Capital Strategies LLC now owns 36,871 shares of the company’s stock worth $385,000 after buying an additional 13,703 shares during the last quarter. 56.95% of the stock is owned by institutional investors and hedge funds.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.